Physiomics Regulatory News (PYC)

6 August 2025

Physiomics plc

("Physiomics" or the "Company")

Physiomics Awarded Follow-on Contract with UK Biotech Client

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the award of a second contract by a UK-based biotech client at the forefront of AI-driven drug development. This follows the successful completion of a previous project with the same client, which was announced in June 2024 and fell into the Company's Modelling and Simulation division.

Under the new contract, Physiomics will update a model previously developed for the client, incorporating clinical data from their ongoing Phase 1 study. The updated model will be used to support critical decisions regarding future clinical dosing strategy. The project will leverage Physiomics' proprietary Virtual Tumour™ platform and is expected to be completed over the next two months. The project is valued at approximately £38,000.

Dr Peter Sargent, CEO of Physiomics, commented:

"We're delighted to be working again with this valued client and to continue supporting the development of their oncology programme. This follow-on project provides a strong opportunity for our Virtual Tumour platform to help guide important clinical decisions and demonstrates the growing impact of model-informed approaches in dose optimisation decisions."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.